A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether statins slow the process of calcification of aortic tissue valves. Altogether 207 papers were found using the reported search, of which eight represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. We acknowledge the limited evidence in this very specific field of cardiac surgery. Due to their pleiotropic effects, including anti-inflammatory properties, there has been speculation that statins could reduce and delay the degeneration and calcification of aortic bioprosthetic valves. Mainly, it was extrapolation of the recently discovered molecular similarities between atherosclerosis and native aortic valve stenosis (AS), with some evidence that statins may slow the progression of native aortic valve calcific degeneration, and the potential harmful impact of atherosclerotic risk factors on the development of native AS. Several studies have been conducted to evaluate the impact of hyperlipidemia and serum cholesterol levels on structural valve deterioration (SVD). Indeed, two studies suggested hyperlipidemia was a risk factor for SVD and correlated reoperation, from which one case-control study based on first-generation biological valves without specific anti-calcification treatment, while three -more convincing by number of patients observed and design of the study -reported contrary results. The other three studies focused on statin treatment in patients after aortic biological valve replacement. Two studies confirmed beneficial effects of statin therapy on valve hemodynamics or inflammatory damage in vivo, but another study, with significantly greater patients series, found lipid-lowering therapy futile in this clinical aspect. Currently, studies and their results are discordant, but statin therapy appears insufficient to result in better clinical outcomes. We conclude that even though the data is conflicting, statin therapy does not prevent SVD of bioprosthetic valves in the aortic position.
Introduction
A best evidence topic was constructed according to a structured protocol. This is fully described in ICVTS w1x.
Three-part question
In wpatients following a bioprosthetic aortic valve replacementx is wstatin therapyx effective in wpreventing tissue valve deteriorationx?
Clinical scenario
Five days ago you replaced a severely calcified aortic valve with a bioprosthesis in a 75-year-old patient. He recovered very well and at discharge he asks you and the team if any of his tablets will stop this new valve calcifying in the same way that his old valve calcified. Your registrar confidently tells him that the statins will do this, but you are less sure and thus resolve to look up the answer before he goes home.
Search strategy
Medline 1950-December 2009 using OVID interface wexp Heart Valve ProsthesisyOR exp Heart Valve Prosthesis ImplantationyOR aortic valve.mp. or exp Aortic Valveyx AND wexp Anticholesteremic Agentsyor Statin$.mp OR atorvastatin.mp OR simvastatin.mp OR pravastatin.mp OR ceruvastatin.mpx.
Search outcome
Two hundred and seven papers were found using the reported search, in addition, the reference lists of all relevant articles were searched. From these eight papers the best evidence to answer the question was found. These are presented in Table 1 .
Results
David and Ivanov w2x did not confirm a role of hyperlipidemia in predicting freedom from reoperation after aortic valve replacement with bioprosthetic valves. However, the authors cautioned that the probability of valve failure in Downloaded from https://academic.oup.com/icvts/article-abstract/11/3/297/814377 by guest on 10 April 2019 Gilmanov et al. / Interactive CardioVascular and Thoracic Surgery 11 (2010) patients with atherosclerosis risk factors was reduced because most of them were actually taking statins.
Farivar and Cohn w3x found that serum cholesterol, younger age and coronary artery disease were linked to calcification of first-generation aortic bioprosthetic valves. Case-control analysis of the explanted tissue valves showed that the mean serum cholesterol level in the explanted valve group was significantly higher (P-0.0001) than that of those who did not need re-replacement (the odds ratio (OR) for valve explantation and re-replacement was 3.9-fold higher for serum cholesterol levels )5.18 mmolyl).
Gring et al. w4x from the evaluation of 7150 patients which included 208 explants for structural valve deterioration (SVD) showed that only younger age, greater body weight, elevated serum creatinine level and use of a pericardial valve predicted SVD. Neither preoperative cholesterol nor its fractions predicted valve explant for SVD. Moreover, no cardiovascular risk factors were predictive of SVD.
Le Tourneau et al. w5x investigated 222 patients, who underwent surgery for severe aortic valve stenosis (AS). Independent predictors of mortality were age, diabetes mellitus (DM), male gender, and New York Heart Association D. Gilmanov et al. / Interactive CardioVascular and Thoracic Surgery 11 (2010) [297] [298] [299] [300] [301] [302] Best Evidence Topic (NYHA) class. DM and NYHA class were also independent predictive factors for valve-related death and overall valverelated complications. The only independent predictive risk factor of structural valve failure in multivariate analysis was renal failure. Cardiovascular risk factors, such as hypercholesterolemia, DM, hypertension, tobacco smoking and obesity had no effect on the outcome of the bioprosthesis.
Nollert et al. w6x found that in patients 57 years of age or younger, female sex, DM, smoking and an increased cholesterol level were significantly associated with reoperation. Valve longevity was 2.2 years longer for cholesterol levels 6.21 mmolyl or lower compared with cholesterol levels higher than 6.21 mmolyl. There was no relation between any of these parameters and valve dysfunction among patients older than 57 years of age. While the study suggested a relationship between hypercholesterolemia and bioprosthetic degeneration, other confounding factors limited the validity of authors' conclusions w2x.
Antonini-Canterin et al. w7, 8x retrospectively selected 167 patients with bioprosthetic aortic valves. The annual rate of increase in peak prosthetic velocity, the annual rates of decrease in prosthetic effective orifice area and indexed effective orifice area were lower in statin-treated patients. Worsening of aortic regurgitation was 3.6 times less common in the statin group vs. controls. The OR for progression of prosthetic degeneration with statin treatment was 0.13. The only factor associated with a lower progression of bioprosthetic aortic valve failure was statin treatment.
Kulik et al. w9x followed 1193 patients and 150 of them received lipid lowering therapy (LLT, including statins) early after surgery. The progression of peak and mean transprosthetic gradients during echocardiographic follow-up was equivalent between patients treated with and without LLT. The annualized linear rate of gradient progression following valve replacement was also similar between groups. The incidence of mild or greater aortic insufficiency on the most recent echocardiogram was comparable, and there was no difference in the 10-year freedom from reoperation for SVD between the two groups. Skowasch et al. w10x analyzed the endstage degenerative aortic valve tissue from native valves, degenerated bioprostheses and tissue from non-stenosed native and nonimplanted bioprosthetic control valves. They found a raised C-reactive protein (CRP) 3.7 times more frequently in bioprostheses than in native valves, also the serum CRP levels increased in patients with aortic valve bioprostheses showing a significant correlation with the valvular inflammatory process. Association of statin treatment with decreases in both valvar and serum CRP concentrations was verified suggesting possible pleiotropic andyor anti-inflammatory properties of these molecules.
Clinical bottom line
We acknowledge the limited evidence in this very specific field of cardiac surgery. Due to their pleiotropic effects, there has been speculation that statins could reduce and delay the degeneration and calcification of aortic bioprosthetic valves. Several studies have been conducted to evaluate the impact of hyperlipidemia and serum cholesterol levels on SVD. Indeed, two studies suggested hyperlipidemia was a risk factor for SVD and correlated reoperation, from which there was one case-control study based on first-generation biological valves without specific anti-calcification treatment, while three reported contrary results. The other three studies focused on statin treatment in patients after aortic biological valve replacement. Two studies confirmed beneficial effects of statin therapy on valve hemodynamics or inflammatory damage in vivo, but another study, with a significantly greater patients series, found LLT ineffectual in this clinical aspect. Currently, studies and their results are discordant, but statin therapy appears insufficient to provide better clinical outcomes. We conclude that even though the data is conflicting, statin therapy does not prevent SVD of bioprosthetic valves in the aortic position.
debates. Especially, aortic valve stenosis is characterized by atherosclerosislike lesions, consisting of activated inflammatory cells, including T lymphocytes, macrophages, and of lipid deposits, calcific nodules, and bone tissue. Active mediators of calcification and cells with osteoblast-like activity are present in diseased valves. Moreover, extracellular matrix remodeling, including collagen synthesis and elastin degradation by matrix metalloproteinases and cathepsins, contributes to leaflet stiffening w2x.
Notably, several experimental studies have proved the inhibition of hypercholesterolemia-induced calcification of aortic valve in animal models. Rajamannan et al. w3x demonstrated that atorvastatin inhibits aortic valve calcification reducing bone-formation and cellular proliferation via Lrp5 receptor pathway as well as enhancing nitric oxide synthase production. Thus, Monzack et al. w4x applied multiple in vitro disease stimuli to valvular interstitial cell (VIC) cultures and examined the impact of simvastatin treatment on VIC function. Simvastatin inhibited calcific nodule formation in a dose-dependent manner on all materials (although the level of statin efficacy was highly substrate-dependent), while decreases in nodule formation were not achieved via the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase pathway, but were correlated with decreases in Rho kinase (ROCK) activity.
Moreover, unpublished data from our experimental protocols are in accordance with the above evidence. Particularly, New Zealand rabbits (ns10) fed with 4% cholesterol diet and treated with simvastatin (5 mg/kg) for eight weeks revealed a statistical significant inhibition of aortic valve atherosclerosis (P-0.001) compared to cholesterol fed rabbits (ns10). Thus, similar statistical significant inhibition of atherogenesis demonstrated the histopathological examination of ascending and descending aortas of simvastatin-treated hypercholesterolemic rabbits compared to hypercholesterolemic animals. Indeed, ascending/descending aortas of simvastatin-treated rabbits presented type I-II lesions according to AHA classification of atherosclerosis, while cholesterol fed animals revealed lesions of type IV-V compatible with atheroma.
A key point that should be discussed is the high-dose of simvastatin (5 mg/kg) in a plethora of experimental protocols in the literature. In our opinion, the above dose -being safe and non-toxic in rabbits (according to FDAs recommendations) -may be responsible for simvastatins anti-inflammatory and anti-oxidative effects contributing to inhibition of atherogenesis.
In addition, Lorusso et al. w5x demonstrated that atorvastatin significantly attenuates post-implant structural degeneration of artificial valve bovine pericardial tissue that was subcutaneously implanted in mice.
In conclusion, based on personal data concerning the aortic valve and ascending/descending aorta in hypercholesterolemic rabbits, we support the beneficial impact of simvastatin in inhibition of hypercholesterolemiainduced atherosclerosis in rabbits. Even if statins do not prevent SVD of aortic bioprosthetic valves, they are associated with several beneficial actions in patients undergoing cardiac valve replacement w2x. Firstly, statins improve renal function w2x. Renal dysfunction is a strong predictor of mortality in patients undergoing valve surgery w2x; thus, statins may influence mortality rates following valve surgery in this indirect way. Secondly, postoperative atrial fibrillation is a common complication following cardiac surgery and is associated with considerable morbidity including stroke, ventricular arrhythmias, heart failure, myocardial infarction, prolonged hospital stay, as well as short-and long-term mortality w3x. High-dose statin administration successfully reduces the incidence of postoperative atrial fibrillation w3x. Thirdly, there is evidence suggesting that preoperative statin use is associated with a reduction in the patients' odds of developing a postoperative infection following cardiac surgery w4x. Finally, a large (ns3829 patients; 1044 statin users; 2785 statin non-users), eight-year retrospective study on patients undergoing cardiac surgery concluded that statin use is associated with improved postoperative mortality and morbidity rates in these patients w5x.
In conclusion, although the data regarding this issue is indeed conflicting, it may be misleading to conclude that statins do not prevent SVD and should therefore not be prescribed to patients undergoing aortic bioprosthetic valve replacement w1x. Due to their pleiotropic effects w2-5x, statins should be prescribed to these patients, whether they prevent SVD or not. Ideally, statins should be employed preoperatively w4, 5x. However, statin treatment is associated with several beneficial actions in patients undergoing heart valve surgery even if initiated postoperatively w2x. Thus, routine statin use in patients undergoing heart valve surgery should probably be recommended.
